human pd 1 antibodies Search Results


97
R&D Systems mouse monoclonal antibody for ido
Mouse Monoclonal Antibody For Ido, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pm29848687-56-8-14?v=R%26D+Systems
Average 97 stars, based on 1 article reviews
mouse monoclonal antibody for ido - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

93
Miltenyi Biotec cd4 vit4 mouse igg2a
Cd4 Vit4 Mouse Igg2a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/10__1038_slash_S41467___021___21774___4____41467_2021_21774_MOESM14_ESM-26-153-151?v=Miltenyi+Biotec
Average 93 stars, based on 1 article reviews
cd4 vit4 mouse igg2a - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
Miltenyi Biotec 130 117 384 ab 2727929 cd303 bv421 201a
130 117 384 Ab 2727929 Cd303 Bv421 201a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pmc12371032__41467_2025_63069_MOESM1_ESM-162-204-202?v=Miltenyi+Biotec
Average 94 stars, based on 1 article reviews
130 117 384 ab 2727929 cd303 bv421 201a - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
R&D Systems human pd 1 antibody
Human Pd 1 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pm40044819-36-66-70?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human pd 1 antibody - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

91
R&D Systems pd1 alx488
This figure shows LN analysis from 3 different participants before vaccination and again at week 2 after vaccination. Participant 1996 has recognizable follicles before vaccination and formation of follicles after vaccination. The accumulation of <t>PD1</t> staining cells within the secondary follicle (D) with green and blue staining cells in the secondary follicle (staining yellow) show an expected reaction to vaccination. Panel B shows participant 1682 with fewer, more poorly formed follicles at baseline and a lack of recognizable secondary follicles with vaccination. PD1 staining cells are not inside of the follicle structure. Participant 1688 has no recognizable follicles prior to vaccination and no response to vaccination. Scale bar indicates 20 μm.
Pd1 Alx488, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pmc06025977-380-29-32?v=R%26D+Systems
Average 91 stars, based on 1 article reviews
pd1 alx488 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

93
R&D Systems anti pd 1
This figure shows LN analysis from 3 different participants before vaccination and again at week 2 after vaccination. Participant 1996 has recognizable follicles before vaccination and formation of follicles after vaccination. The accumulation of <t>PD1</t> staining cells within the secondary follicle (D) with green and blue staining cells in the secondary follicle (staining yellow) show an expected reaction to vaccination. Panel B shows participant 1682 with fewer, more poorly formed follicles at baseline and a lack of recognizable secondary follicles with vaccination. PD1 staining cells are not inside of the follicle structure. Participant 1688 has no recognizable follicles prior to vaccination and no response to vaccination. Scale bar indicates 20 μm.
Anti Pd 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pmc06880756-288-109-110?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
anti pd 1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
R&D Systems human pd1
This figure shows LN analysis from 3 different participants before vaccination and again at week 2 after vaccination. Participant 1996 has recognizable follicles before vaccination and formation of follicles after vaccination. The accumulation of <t>PD1</t> staining cells within the secondary follicle (D) with green and blue staining cells in the secondary follicle (staining yellow) show an expected reaction to vaccination. Panel B shows participant 1682 with fewer, more poorly formed follicles at baseline and a lack of recognizable secondary follicles with vaccination. PD1 staining cells are not inside of the follicle structure. Participant 1688 has no recognizable follicles prior to vaccination and no response to vaccination. Scale bar indicates 20 μm.
Human Pd1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pm22120117-498-93-98?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
human pd1 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
R&D Systems anti pd 1 ab
Protein levels of exosomes and RFVs <t>of</t> <t>PD-1+</t> or PD-L1+ exosomes in plasma of patients with HNSCC. A. protein concentrations of exosomes (μg/ml plasma) are significantly elevated in patients with active disease (AD) relative to those with no evidence of disease after therapy (NED); B. RFVs for PD-L1+ exosomes is significantly higher in AD patients, patients with positive lymph nodes and patients with the high (III/IV) UICC stage tumors at diagnosis. * p< 0.05; *** p< 0.0008. C. RFVs for PD-1 exosomes in plasma are not statistically different in HNSCC patients stratified by disease activity, lymph node or UICC status. The data presented as box plots are normalized to the frequency of exosomes/1mL of patients’ plasma in this and the subsequent figures.
Anti Pd 1 Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pmc06126905-198-1-8?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
anti pd 1 ab - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
R&D Systems alexa fluor 488 anti hpd 1 antibody
Protein levels of exosomes and RFVs <t>of</t> <t>PD-1+</t> or PD-L1+ exosomes in plasma of patients with HNSCC. A. protein concentrations of exosomes (μg/ml plasma) are significantly elevated in patients with active disease (AD) relative to those with no evidence of disease after therapy (NED); B. RFVs for PD-L1+ exosomes is significantly higher in AD patients, patients with positive lymph nodes and patients with the high (III/IV) UICC stage tumors at diagnosis. * p< 0.05; *** p< 0.0008. C. RFVs for PD-1 exosomes in plasma are not statistically different in HNSCC patients stratified by disease activity, lymph node or UICC status. The data presented as box plots are normalized to the frequency of exosomes/1mL of patients’ plasma in this and the subsequent figures.
Alexa Fluor 488 Anti Hpd 1 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pm39814862-153-4-9?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
alexa fluor 488 anti hpd 1 antibody - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

91
R&D Systems reporting summary
Protein levels of exosomes and RFVs <t>of</t> <t>PD-1+</t> or PD-L1+ exosomes in plasma of patients with HNSCC. A. protein concentrations of exosomes (μg/ml plasma) are significantly elevated in patients with active disease (AD) relative to those with no evidence of disease after therapy (NED); B. RFVs for PD-L1+ exosomes is significantly higher in AD patients, patients with positive lymph nodes and patients with the high (III/IV) UICC stage tumors at diagnosis. * p< 0.05; *** p< 0.0008. C. RFVs for PD-1 exosomes in plasma are not statistically different in HNSCC patients stratified by disease activity, lymph node or UICC status. The data presented as box plots are normalized to the frequency of exosomes/1mL of patients’ plasma in this and the subsequent figures.
Reporting Summary, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pmc07933278__41467_2021_21572_MOESM3_ESM-38-73-92?v=R%26D+Systems
Average 91 stars, based on 1 article reviews
reporting summary - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

93
R&D Systems mab10861
Protein levels of exosomes and RFVs <t>of</t> <t>PD-1+</t> or PD-L1+ exosomes in plasma of patients with HNSCC. A. protein concentrations of exosomes (μg/ml plasma) are significantly elevated in patients with active disease (AD) relative to those with no evidence of disease after therapy (NED); B. RFVs for PD-L1+ exosomes is significantly higher in AD patients, patients with positive lymph nodes and patients with the high (III/IV) UICC stage tumors at diagnosis. * p< 0.05; *** p< 0.0008. C. RFVs for PD-1 exosomes in plasma are not statistically different in HNSCC patients stratified by disease activity, lymph node or UICC status. The data presented as box plots are normalized to the frequency of exosomes/1mL of patients’ plasma in this and the subsequent figures.
Mab10861, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/bio_rxiv__739342-255-30-31?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
mab10861 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Elabscience Biotechnology anti human apc cd279 pd 1
Protein levels of exosomes and RFVs <t>of</t> <t>PD-1+</t> or PD-L1+ exosomes in plasma of patients with HNSCC. A. protein concentrations of exosomes (μg/ml plasma) are significantly elevated in patients with active disease (AD) relative to those with no evidence of disease after therapy (NED); B. RFVs for PD-L1+ exosomes is significantly higher in AD patients, patients with positive lymph nodes and patients with the high (III/IV) UICC stage tumors at diagnosis. * p< 0.05; *** p< 0.0008. C. RFVs for PD-1 exosomes in plasma are not statistically different in HNSCC patients stratified by disease activity, lymph node or UICC status. The data presented as box plots are normalized to the frequency of exosomes/1mL of patients’ plasma in this and the subsequent figures.
Anti Human Apc Cd279 Pd 1, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pd+1+antibodies/pmc12858834-69-7-11?v=Elabscience+Biotechnology
Average 93 stars, based on 1 article reviews
anti human apc cd279 pd 1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


This figure shows LN analysis from 3 different participants before vaccination and again at week 2 after vaccination. Participant 1996 has recognizable follicles before vaccination and formation of follicles after vaccination. The accumulation of PD1 staining cells within the secondary follicle (D) with green and blue staining cells in the secondary follicle (staining yellow) show an expected reaction to vaccination. Panel B shows participant 1682 with fewer, more poorly formed follicles at baseline and a lack of recognizable secondary follicles with vaccination. PD1 staining cells are not inside of the follicle structure. Participant 1688 has no recognizable follicles prior to vaccination and no response to vaccination. Scale bar indicates 20 μm.

Journal: The Journal of Clinical Investigation

Article Title: Lymphoid tissue fibrosis is associated with impaired vaccine responses

doi: 10.1172/JCI97377

Figure Lengend Snippet: This figure shows LN analysis from 3 different participants before vaccination and again at week 2 after vaccination. Participant 1996 has recognizable follicles before vaccination and formation of follicles after vaccination. The accumulation of PD1 staining cells within the secondary follicle (D) with green and blue staining cells in the secondary follicle (staining yellow) show an expected reaction to vaccination. Panel B shows participant 1682 with fewer, more poorly formed follicles at baseline and a lack of recognizable secondary follicles with vaccination. PD1 staining cells are not inside of the follicle structure. Participant 1688 has no recognizable follicles prior to vaccination and no response to vaccination. Scale bar indicates 20 μm.

Article Snippet: Slides were then washed 3 times in PBS for a total of 60 minutes and stained for 2 hours at RT with titrated amounts of the following conjugated antibodies: PD1-Alx488 (catalog FAB7115G; R&D Systems), CD20-efluor615 (clone L26; eBioscience), Ki67-Alx647 (clone B56; BD Biosciences), CD57-Alx680 (clone NK-1; in-house conjugated).

Techniques: Staining

Protein levels of exosomes and RFVs of PD-1+ or PD-L1+ exosomes in plasma of patients with HNSCC. A. protein concentrations of exosomes (μg/ml plasma) are significantly elevated in patients with active disease (AD) relative to those with no evidence of disease after therapy (NED); B. RFVs for PD-L1+ exosomes is significantly higher in AD patients, patients with positive lymph nodes and patients with the high (III/IV) UICC stage tumors at diagnosis. * p< 0.05; *** p< 0.0008. C. RFVs for PD-1 exosomes in plasma are not statistically different in HNSCC patients stratified by disease activity, lymph node or UICC status. The data presented as box plots are normalized to the frequency of exosomes/1mL of patients’ plasma in this and the subsequent figures.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Clinical significance of PD-L1 + exosomes in plasma of Head and Neck Cancer patients

doi: 10.1158/1078-0432.CCR-17-2664

Figure Lengend Snippet: Protein levels of exosomes and RFVs of PD-1+ or PD-L1+ exosomes in plasma of patients with HNSCC. A. protein concentrations of exosomes (μg/ml plasma) are significantly elevated in patients with active disease (AD) relative to those with no evidence of disease after therapy (NED); B. RFVs for PD-L1+ exosomes is significantly higher in AD patients, patients with positive lymph nodes and patients with the high (III/IV) UICC stage tumors at diagnosis. * p< 0.05; *** p< 0.0008. C. RFVs for PD-1 exosomes in plasma are not statistically different in HNSCC patients stratified by disease activity, lymph node or UICC status. The data presented as box plots are normalized to the frequency of exosomes/1mL of patients’ plasma in this and the subsequent figures.

Article Snippet: Next, anti-PD-1 Ab, #AF1086 lot #ICA02 (purchased from R&D Systems) was used to block effects of exosome-mediated suppression.

Techniques: Activity Assay

RFVs for PD-L1+ and PD-1+ exosomes/mL plasma and levels of sPD-L1 in plasma of HNSCC patients. A. No correlation between RFVs for PD-L1+ and PD-1+ exosomes in plasma of HNSCC patients was observed: Spearman’s correlation at p=0.7, r=0.05. B. No correlation between RFVs for PD-L1+ exosomes in patients’ plasma and soluble PD-L1; Spearman’s correlation at p=0.85, r=0.03.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Clinical significance of PD-L1 + exosomes in plasma of Head and Neck Cancer patients

doi: 10.1158/1078-0432.CCR-17-2664

Figure Lengend Snippet: RFVs for PD-L1+ and PD-1+ exosomes/mL plasma and levels of sPD-L1 in plasma of HNSCC patients. A. No correlation between RFVs for PD-L1+ and PD-1+ exosomes in plasma of HNSCC patients was observed: Spearman’s correlation at p=0.7, r=0.05. B. No correlation between RFVs for PD-L1+ exosomes in patients’ plasma and soluble PD-L1; Spearman’s correlation at p=0.85, r=0.03.

Article Snippet: Next, anti-PD-1 Ab, #AF1086 lot #ICA02 (purchased from R&D Systems) was used to block effects of exosome-mediated suppression.

Techniques:

CD69 and PD-1 expression on activated CD8+ T cells and down-regulation of CD69 expression by PD-L1high but not by PD-L1low exosomes. A. Representative flow cytometry showing expression levels of CD69 or PD-1 on the surface of activated CD8+ T cells. Decreasing levels of CD8+CD69+ on the surface of T cells co-incubated with PD-L1high exosomes. B, Downregulation of CD69 expression (% and MFI) on CD8+ T-cells after co-incubation with PD-L1high exosomes. In C, blocking of exosome-mediated down-regulation of CD69 expression on CD8+ T cells by anti-PD-1 Ab. Note that inhibition mediated by PD-L1high exosomes was almost completely reversed (% and MFI) by adding the PD-1 inhibitor. * p< 0.05; ** p<0.005

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Clinical significance of PD-L1 + exosomes in plasma of Head and Neck Cancer patients

doi: 10.1158/1078-0432.CCR-17-2664

Figure Lengend Snippet: CD69 and PD-1 expression on activated CD8+ T cells and down-regulation of CD69 expression by PD-L1high but not by PD-L1low exosomes. A. Representative flow cytometry showing expression levels of CD69 or PD-1 on the surface of activated CD8+ T cells. Decreasing levels of CD8+CD69+ on the surface of T cells co-incubated with PD-L1high exosomes. B, Downregulation of CD69 expression (% and MFI) on CD8+ T-cells after co-incubation with PD-L1high exosomes. In C, blocking of exosome-mediated down-regulation of CD69 expression on CD8+ T cells by anti-PD-1 Ab. Note that inhibition mediated by PD-L1high exosomes was almost completely reversed (% and MFI) by adding the PD-1 inhibitor. * p< 0.05; ** p<0.005

Article Snippet: Next, anti-PD-1 Ab, #AF1086 lot #ICA02 (purchased from R&D Systems) was used to block effects of exosome-mediated suppression.

Techniques: Expressing, Flow Cytometry, Incubation, Blocking Assay, Inhibition